<DOC>
	<DOCNO>NCT02893709</DOCNO>
	<brief_summary>The objective study examine effect ethnicity , gender , proton pump inhibitor ( PPI , omeprazole ) , human gut microbiome . The investigator hypothesize PPI therapy might perturb microbial community alter gut microbiome . Young , healthy subject Chinese , Malay Indian ancestry , enrol . They require provide baseline stool sample ( Day 1 ) give course omeprazole therapeutic dose ( 20 mg daily ) duration 7 day . Stool sample collect Day 7 Day 14 ( one week stop omeprazole ) . The DNA sample subject 16S ribosomal ribonucleic acid ( rRNA ) sequencing .</brief_summary>
	<brief_title>Factors Influencing Human Gut Microbiome Profile Multi-ethnic Groups Singapore Community ( FAMES )</brief_title>
	<detailed_description>Background Aim : The objective study examine effect ethnicity , gender , proton pump inhibitor ( PPI , omeprazole ) , human gut microbiome . PPIs commonly use treatment acid-related disorder . The investigator hypothesize PPI therapy might perturb microbial community alter gut microbiome . Methods : Healthy subject Chinese ( n=12 ) , Malay ( n=12 ) Indian ( n=10 ) ancestry , age 21-37 year old , enrol . They require provide baseline stool sample ( Day 1 ) give course omeprazole therapeutic dose ( 20 mg daily ) duration 7 day . Stool sample collect Day 7 Day 14 ( one week stop omeprazole ) . Microbial DNA extract stool sample . This follow PCR , library construction , 16S rRNA sequence use Illumina MiSEQ , statistical bioinformatics analysis .</detailed_description>
	<mesh_term>Gastroesophageal Reflux</mesh_term>
	<mesh_term>Omeprazole</mesh_term>
	<criteria>1 . Provision sign write informed consent , 2 . Aged 2135 year age , 3 . Chinese , Malay Indian ancestry three generation , 4 . Clinical laboratory assessment result within normal limit , unless deviation consider clinically significant investigator , 5 . Subject healthy clinically significant disease condition determine medical history , physical examination , result clinical laboratory test perform within 2 week baseline visit Day 1 , 6 . Ability communicate investigator understand comply requirement study participation . 7 . Female subject must first half menstrual cycle ( i.e . 1 14 day end previous menstruation ) Research Study entry . 1 . Any acute illness within 2 week Day 1 , unless otherwise approve PI , 2 . Presence chronic illness e.g . diabetes , renal disease , gastrointestinal disease , etc. , , opinion investigator , could compromise data study , 3 . Subjects declare positive HIV viral hepatitis ( Hepatitis A , B , C ) , 4 . Treatment within previous 3 month antibiotic , 5 . Treatment prescription overthecounter ( OTC ) medication , herbal supplement within 4 week Day 1 unless approve PI , 6 . Consumption probiotic lactobacilluscontaining product e.g . Yakult , Vitagen Yogurt within 4 week Day 1 unless approve PI , 7 . Abnormal biochemistry indicator , 8 . Poor peripheral venous access , 9 . Involvement plan conduct study , 10 . Irregular bowel habit complain constipation problem .</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>37 Years</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>